Cell Reports (May 2024)

Prophylactic treatment with the c-Abl inhibitor, neurotinib, diminishes neuronal damage and the convulsive state in pilocarpine-induced mice

  • América Chandía-Cristi,
  • Daniela A. Gutiérrez,
  • Andrés E. Dulcey,
  • Marcelo Lara,
  • Lina Vargas,
  • Yi-Han Lin,
  • Pablo Jimenez-Muñoz,
  • Gabriela Larenas,
  • Xin Xu,
  • Amy Wang,
  • Ashley Owens,
  • Christopher Dextras,
  • YuChi Chen,
  • Claudio Pinto,
  • Tamara Marín,
  • Hugo Almarza-Salazar,
  • Keryma Acevedo,
  • Gonzalo I. Cancino,
  • Xin Hu,
  • Patricio Rojas,
  • Marc Ferrer,
  • Noel Southall,
  • Mark J. Henderson,
  • Silvana Zanlungo,
  • Juan J. Marugan,
  • Alejandra Álvarez R

Journal volume & issue
Vol. 43, no. 5
p. 114144

Abstract

Read online

Summary: The molecular mechanisms underlying seizure generation remain elusive, yet they are crucial for developing effective treatments for epilepsy. The current study shows that inhibiting c-Abl tyrosine kinase prevents apoptosis, reduces dendritic spine loss, and maintains N-methyl-d-aspartate (NMDA) receptor subunit 2B (NR2B) phosphorylated in in vitro models of excitotoxicity. Pilocarpine-induced status epilepticus (SE) in mice promotes c-Abl phosphorylation, and disrupting c-Abl activity leads to fewer seizures, increases latency toward SE, and improved animal survival. Currently, clinically used c-Abl inhibitors are non-selective and have poor brain penetration. The allosteric c-Abl inhibitor, neurotinib, used here has favorable potency, selectivity, pharmacokinetics, and vastly improved brain penetration. Neurotinib-administered mice have fewer seizures and improved survival following pilocarpine-SE induction. Our findings reveal c-Abl kinase activation as a key factor in ictogenesis and highlight the impact of its inhibition in preventing the insurgence of epileptic-like seizures in rodents and humans.

Keywords